At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
TAK-831 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of TAK 831 in Healthy Adult Asian Subjects
In Brief
A Phase 1 clinical trial evaluating TAK-831 and Placebo for Healthy Volunteers. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-831 when administered as single or multiple oral doses in healthy adult Asian participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesJapan
CollaboratorsTakeda
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartOct 2018
Primary CompletionJun 2019
Study CompletionJun 2019
TodayJul 2026
First PostedSep 27, 2018
Enrollment StartOct 9, 2018
Primary CompletionJun 9, 2019
Study CompletionJun 19, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.8 years ago
Interventions
TAK-831drug
TAK-831 Tablets.
Placebodrug
TAK-831 Matching Placebo Tablets.